Heparin manufacturer faces trial challenges

According to an article in the Wall Street Journal, Baxter International Inc., maker of heparin, is facing challenges about disclosure regarding the 2008 heparin contamination debacle.

The crux of the matter has to do with revealing the Chinese supply chain during the depositions. Baxter's competitors who are seeking FDA approval for a newer more expensive kind of blood thinner want otherwise.

The Chinese contamination crisis was linked to 81 heparin deaths in the U.S. in 2008.

Baxter has denied negligence in the deaths linked to heparin.